8/11/2022

speaker
Operator

Good morning. Welcome to Synlogic's second quarter 2022 conference call. At this time, all participants are in a listen-only mode. There will be a question and answer session at the end of this call. Please be advised that this call is being recorded. I would now like to turn the call over to Andrew Funderburg of Kendall Investor Relations.

speaker
Andrew Funderburg
Vice President, Investor Relations (Kendall Investor Relations)

Please proceed. Thank you, Operator.

speaker
Andrew Funderburg
Vice President, Investor Relations (Kendall Investor Relations)

Good morning and thank you for joining us on today's conference call. This morning we issued a press release which outlines our second quarter 2022 financial results and additional business updates. The release is available on the investor section of our website at www.synlogictx.com. Joining me on this call are Dr. Aoife Brennan, President and Chief Executive Officer, Molly Harper, Chief Business Officer, Dave Hava, Chief Scientific Officer, and Michael Jensen, Chief Financial Officer. Other members of the management team will be available during the Q&A. During the call, IFA will provide a review of this quarter's highlights. Molly will provide additional detail for the clinical programs. Dave will discuss our earlier stage programs and collaborations. And Michael will provide a financial overview. Following our prepared remarks, we will open the call for questions. As we begin, I'd like to remind everyone that comments today may include forward-looking statements made under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date hereof and are subject to numerous factors, assumptions, risks, and uncertainties, which change over time. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including those described under the heading Forward-Looking Statements in Synlogic's press release from earlier today or under the heading Risk Factors in Synlogic's most recent Form 10-K or in later filings with the SEC. Synlogic cautions you not to place undue reliance on any forward-looking statement. Now, I'd like to turn the call over to Aoife.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-